HOME >> MEDICINE >> NEWS
First Trial Comparing Adderall To Ritalin For ADHD Shows It To Be Longer-Lasting, Equally As Effective

BUFFALO, N.Y. -- The first trial of comparable doses of Ritalin, the standard treatment for children with attention deficit/hyperactivity disorder (ADHD), and Adderall, another drug used to treat ADHD, has shown that Adderall lasts longer than Ritalin and is at least as effective.

In addition, staff supervising and observing the children during the trial, who were blinded to the treatment regimen, preferred Adderall three-to-one over Ritalin as a continuing treatment.

Results of the study, led by William R. Pelham, Ph.D., professor of psychology in the University at Buffalo College of Arts and Sciences and director of UB's Attention Deficit Disorder Program, appear in the April issue of Pediatrics.

Pelham concluded that, based on the trial findings, Adderall should be added to the repertoire of effective treatments for ADHD, especially for children in which Ritalin dissipates rapidly and who need a longer-acting medication.

The first studies of Adderall's action had suggested that its effect lasts longer than Ritalin's, raising the possibility of eliminating a mid-day dose of ADHD medication in school, a requirement that is intrusive, potentially stigmatizing and often results in poor compliance, Pelham said. Ritalin is absorbed quickly, and its effects begin to diminish after three hours. This study was designed to compare the ability of the two drugs to control ADHD symptoms over time.

The trial involved 25 children -- 21 boys and five girls -- who took part in an eight-week ADHD summer treatment program developed by Pelham and conducted at UB. The program is structured somewhat like a day-camp, with intensive behavioral treatment using a point system carried out in academic, social and recreational settings. The children spent nine hours a day in the program.

Each child received one of the following medications twice a day, every day, in random order: 10 mg of Ritalin, 17.5 mg of R
'"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-2626
University at Buffalo
5-Apr-1999


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
(Date:5/20/2013)... Heritage Woods of Gurnee , a ... is hosting Breakfast and Bingo at 8:30 a.m. on ... at 3775 Grand Ave. in Gurnee, Illinois, serves older ... need some help to maintain their independence. , "Come ... bingo," says Tammy Temaner-Rosas, Director of Marketing for Heritage ...
(Date:5/20/2013)... MN (PRWEB) May 20, 2013 When a ... bed is only part of the process. Much of the ... the internet involves not knowing what to expect. Best ... advice consumers can use to ensure their purchase proves smooth. ... You Buy a Mattress Online ”, readers find helpful tips ...
(Date:5/20/2013)... 2013 Fastcare Miami Beach clinic ... within its first symptoms, as if not treated, it may ... serious infection. Although a urinary tract infection in itself is ... serious kidney infection called pyelonephritis. Women seem to have many ... to the same percentage as women after the age of ...
(Date:5/20/2013)... 20, 2013 Eben Pagan's ... the public creating a frenzy among business owners ... elite business training. WealthSpringMarketing.com's Tiffany Hendricks has published ... an exclusive bonus. , "Eben Pagan is a ... training to individuals serious about success," reports Hendricks. ...
(Date:5/20/2013)... May 20, 2013 Leading facial plastic surgeon ... recognized as a “Top Doc” in the field of Otolaryngology ... , The Palm Beacher magazine, one of Palm Beach ... Docs” in the May/June 2013 issue, including 70 of the ... and dining, events, things to do, health and fitness, people ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Gurnee Affordable Assisted Living Community to Host Breakfast and Bingo 2Health News:See What to Expect When You Buy a Mattress Online With Latest Guide From Best Mattress Online 2Health News:Fastcare Advises on How to Prevent a UTI 2Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
Cached News: